Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
Why support-platform strategy may become a differentiator in schizophrenia treatment markets
See why Teva Pharmaceutical Industries Ltd.’s support-platform strategy could reshape schizophrenia treatment markets and competitive positioning. Read more.
Why selective immune homeostasis is the bigger story behind CUE-401
Cue Biopharma’s CUE-401 data points to a bigger autoimmune story. Read why selective immune homeostasis could reshape immunology pipelines.
Why eftilagimod alfa’s soft tissue sarcoma data now matters more than ever for Immutep Limited
Immutep Limited’s soft tissue sarcoma data may now define eftilagimod alfa’s future. Find out why this could reshape its oncology strategy.
How GTIS Partners LP is using Tampa infill logistics to extend its U.S. industrial playbook
GTIS Partners LP is developing 4Ward Logistics Center in Tampa. Read how location, timing, and industrial demand could shape the project’s payoff.
The Hyper deal hints at a bigger AI shift inside American Express Company
Discover how American Express Company’s Hyper acquisition could signal a larger AI transformation in commercial finance and expense management. Read more.
How GTx-104 may improve ICU dosing consistency in subarachnoid hemorrhage
How Grace Therapeutics’ GTx-104 could improve ICU dosing consistency and reshape hospital economics in subarachnoid hemorrhage care. Read the full BNT analysis.
Is elraglusib emerging as a new frontline option in metastatic PDAC?
Read how Actuate Therapeutics’ elraglusib Phase 2 survival data could reshape metastatic PDAC treatment and investor expectations.
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race and what it means for biotech strategy, competition, and valuation. Read more.
How CLR 125 may test the limits of precision radiopharmaceutical therapy in solid tumors
Could CLR 125 redefine precision radiopharmaceutical therapy in solid tumors? Read what this means for Cellectar Biosciences, Inc. and oncology markets.